Message from the President

President, CEO Toshiyasu Miyazaki

Advances in science and medical technology in recent years are remarkable, and the possibility of a cure with regard to many diseases are emerging. However, in diseases such as cancer, leukemia, and lymphoma, the toll of lives is still substantial.
At MT3, we dedicate our days to bring about technological change in the treatment of diseases and to redefine the boundaries of science necessary for such realization. We are committed to the development and provision of novel life science technologies in an endeavor to save more lives.

About MT3

Company Name Malignant Tumor Treatment Technologies, Inc
Founding Date January 1, 2018
Capital ¥ 400 million (Including capital reserve)
Office Location 10F, DF Building,2-2-8 Minami-Aoyama Minato-ku, Tokyo, 107-0062
President, CEO Toshiyasu Miyazaki
Science Advisors Tokyo University of Science Faculty of Science and Technology Honorary professor
Kengo Sakaguchi
Tokyo University of Science Faculty of Science and Technology Honorary professor Fumio sugawara
Research Collaborator Azabu University Faculty of Veterinary Medicine Professor Hiroeki Sahara

Access

10F, DF Building,2-2-8 Minami-Aoyama Minato-ku, Tokyo, 107-0062